Nonlinear Dynamic System Identification in the Spectral Domain Using Particle-Bernstein Polynomials

System identification (SI) is the discipline of inferring mathematical models from unknown dynamic systems using the input/output observations of such systems with or without prior knowledge of some of the system parameters. Many valid algorithms are available in the literature, including Volterra series expansion, Hammerstein–Wiener models, nonlinear auto-regressive moving average model with exogenous inputs (NARMAX) and its derivatives (NARX, NARMA). Different nonlinear estimators can be used for those algorithms, such as polynomials, neural networks or wavelet networks. This paper uses a different approach, named particle-Bernstein polynomials, as an estimator for SI. Moreover, unlike the mentioned algorithms, this approach does not operate in the time domain but rather in the spectral components of the signals through the use of the discrete Karhunen–Loève transform (DKLT). Some experiments are performed to validate this approach using a publicly available dataset based on ground vibration tests recorded from a real F-16 aircraft. The experiments show better results when compared with some of the traditional algorithms, especially for large, heterogeneous datasets such as the one used. In particular, the absolute error obtained with the prosed method is 63% smaller with respect to NARX and from 42% to 62% smaller with respect to various artificial neural network-based approaches

Numerical Investigation of Al-Reinforced CFRP Composite under Low-Velocity Impact

Fibre-reinforced composite materials are widespread in lightweight, high-performance applications. However, polymeric composites generally exhibit a brittle behaviour, which makes them susceptible to impact damage. Even low-velocity impacts can produce delaminations, which cause a substantial reduction of the compressive mechanical properties. Metallic layers have been embedded in composite laminates with the aim to improve their fracture behaviour: aluminium plies can be employed to increase the indentation resistance of Carbon Fibre Reinforced Polymers (CFRP) specimens. For this reason, hybrid fibre-metal laminates are expected to be a viable solution to reduce the damage caused by low-velocity impacts. In this work, CFRP specimens reinforced with aluminium plies were modelled using the finite element method and a cohesive zone model. Cohesive elements based on a traction-separation formulation were embedded at each ply-to-ply interface to enforce delamination damage. Different configurations of the Al reinforcements were studied by varying the position of the aluminium layers between the CFRP plies

Estimate of compressive strength of an unidirectional composite lamina using cross-ply and angle-ply laminates

In this work has been estimated the compressive strength of a unidirectional lamina of a carbon/epoxy composite material, using the cross-ply and angle-ply laminates. Over the years various methods have been developed to deduce compressive properties of composite materials reinforced with long fibres. Each of these methods is characterized by a specific way of applying load to the specimen. The method chosen to perform the compression tests is the Wyoming Combined Loading Compression (CLC) Test Method, described in ASTM D 6641 / D 6641M-09. This method presents many advantages, especially: the load application on the specimen (end load combined with shear load), the reproducibility of measurements and the experimental equipment quite simplified. Six different laminates were tested in compressive tests. They were realized by the same unidirectional prepreg, but with different stacking sequences: two cross-ply [0/90]ns, two angle-ply [0/90/±45]ns and two unidirectional laminates [0]ns and [90]ns. The estimate of the compressive strength of the unidirectional laminates at 0°, was done by an indirect analytical method, developed from the classical lamination theory, and which uses a multiplicative parameter known as Back-out Factor (BF). The BF is determined by using the experimental values obtained from compression tests. Finally, extrapolated data were compared with prepreg manufacturer datashee

Estimate of compressive strength of an unidirectional composite lamina using cross-ply and angle-ply laminates

In this work has been estimated the compressive strength of a unidirectional lamina of a carbon/epoxy composite material, using the cross-ply and angle-ply laminates. Over the years various methods have been developed to deduce compressive properties of composite materials reinforced with long fibres. Each of these methods is characterized by a specific way of applying load to the specimen.The method chosen to perform the compression tests is the Wyoming Combined Loading Compression (CLC) Test Method, described in ASTM D 6641 / D 6641M-09. This method presents many advantages, especially: the load application on the specimen (end load combined with shear load), the reproducibility of measurementsand the experimental equipment quite simplified. Six different laminates were tested in compressive tests. They were realized by the same unidirectional prepreg, but with different stacking sequences: two cross-ply [0/90]ns, two angle-ply [0/90/±45]ns and two unidirectional laminates [0]ns and [90]ns.The estimate of the compressive strength of the unidirectional laminates at 0°, was done by an indirect analytical method, developed from the classical lamination theory, and which uses a multiplicative parameterknown as Back-out Factor (BF). The BF is determined by using the experimental values obtained from compression tests

Randomized Crossover Trial of the Impact of Morning or Evening Dosing of Antihypertensive Agents on 24-Hour Ambulatory Blood Pressure

Some data suggest that nocturnal dosing of antihypertensive agents may reduce cardiovascular outcomes more than daytime dosing. This trial was designed to evaluate whether ambulatory blood pressure monitoring levels differ by timing of drug dosing. Patients aged 18 to 80 years with reasonably controlled hypertension (≤150/≤90 mm Hg) on stable therapy of ≥1 antihypertensive agent were recruited from 2 centers in London and Thessaloniki. Patients were randomized to receive usual therapy either in the morning (6 am–11 am) or evening (6 pm–11 pm) for 12 weeks when participants crossed over to the alternative timing for a further 12 weeks. Clinic blood pressures and a 24-hour recording were taken at baseline, 12, and 24 weeks and routine blood tests were taken at baseline. The study had 80% power to detect 3 mm Hg difference in mean 24-hour systolic blood pressure (α=0.05) by time of dosing. A 2-level hierarchical regression model adjusted for center, period, and sequence was used. Of 103 recruited patients (mean age, 62; 44% female), 95 patients (92%) completed all three 24-hour recordings. Mean 24-hour systolic and diastolic blood pressures did not differ between daytime and evening dosing. Similarly, morning and evening dosing had no differential impact on mean daytime (7 am–10 pm) and nighttime (10 pm–7 am) blood pressure levels nor on clinic levels. Stratification by age (≤65/≥65 years) or sex did not affect results. In summary, among hypertensive patients with reasonably well-controlled blood pressure, the timing of antihypertensive drug administration (morning or evening) did not affect mean 24-hour or clinic blood pressure levels

Lung function decline in relation to diagnostic criteria for airflow obstruction in respiratory symptomatic subjects

Contains fulltext : 108583.pdf (publisher's version ) (Open Access)BACKGROUND: Current COPD guidelines advocate a fixed < 0.70 FEV1/FVC cutpoint to define airflow obstruction. We compared rate of lung function decline in respiratory symptomatic 40+ subjects who were 'obstructive' or 'non-obstructive' according to the fixed and/or age and gender specific lower limit of normal (LLN) FEV1/FVC cutpoints. METHODS: We studied 3,324 respiratory symptomatic subjects referred to primary care diagnostic centres for spirometry. The cohort was subdivided into four categories based on presence or absence of obstruction according to the fixed and LLN FEV1/FVC cutpoints. Postbronchodilator FEV1 decline served as primary outcome to compare subjects between the respective categories. RESULTS: 918 subjects were obstructive according to the fixed FEV1/FVC cutpoint; 389 (42%) of them were non-obstructive according to the LLN cutpoint. In smokers, postbronchodilator FEV1 decline was 21 (SE 3) ml/year in those non-obstructive according to both cutpoints, 21 (7) ml/year in those obstructive according to the fixed but not according to the LLN cutpoint, and 50 (5) ml/year in those obstructive according to both cutpoints (p = 0.004). CONCLUSION: This study showed that respiratory symptomatic 40+ smokers and non-smokers who show FEV1/FVC values below the fixed 0.70 cutpoint but above their age/gender specific LLN value did not show accelerated FEV1 decline, in contrast with those showing FEV1/FVC values below their LLN cutpoint

The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial

Background: Antiretroviral therapy (ART) has led to dramatic improvements in survival for people living with HIV, but is unable to cure infection, or induce viral control off therapy. Designing intervention trials with novel agents with the potential to confer a period of HIV remission without ART remains a key scientific and community goal. We detail the rationale, design, and outcomes of a randomised, placebo-controlled trial of two HIV-specific long-acting broadly neutralising antibodies (bNAbs): 3BNC117-LS and 10-1074-LS, which target CD4 binding site and V3 loop respectively, on post-treatment viral control. Methods: RIO is a randomised, placebo-controlled, double-blinded prospective phase II study. Eligible individuals will have started ART within 3 months of primary HIV infection and have viral sequences that appear to be sensitive to both bNAbs. It will randomise 72 eligible participants 1:1 to the following arms via a two-stage design. In Stage 1, arm A participants are given dual long-acting (LS-variants) bNAbs infusions, followed by intensively monitored Analytical Treatment Interruption (ATI) (n = 36); in arm B, participants receive placebo infusions followed by ATI. The primary endpoint will be time to viral rebound within 36 weeks after ATI. Upon viral rebound, the participant and researcher are unblinded. Participants in arm A recommence ART and complete the study. Participants in arm B are invited to restart ART and enroll into Stage 2 where they will receive open-label LS bNAbs, followed by a second ATI 24 weeks after. Secondary and exploratory endpoints include adverse events, time to undetectable viraemia after restarting ART, immunological markers, HIV proviral DNA, serum bNAb concentrations in blood, bNAb resistance at viral rebound, and quality of life measures. Discussion: The two-stage design was determined in collaboration with community involvement. This design allows all participants the option to receive bNAbs. It also tests the hypothesis that bNAbs may drive sustained HIV control beyond the duration of detectable bNAb concentrations. Community representatives were involved at all stages. This included the two-stage design, discussion on the criteria to restart ART, frequency of monitoring visits off ART, and reducing the risk of onward transmission to HIV-negative partners. It also included responding to the challenges of COVID-19. Trial registration: The protocol is registered on Clinical.trials.gov and EudraCT and has approval from UK Ethics and MHRA